TC
SAGE

Tarsadia Capital’s Sage Therapeutics SAGE Stock Holding History

Tarsadia Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,000
Closed -$306K – 23
2020
Q3 		$306K Sell
5,000
-20,000
-80% -$1.01M 0.03% 23
2020
Q2 		$1.04M Buy
+25,000
New +$907K 0.18% 30

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tarsadia Capital's SAGE Position: Q4 2020 in Review

Tarsadia Capital sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 5,000 shares — an estimated $306K sold.

Tarsadia Capital first reported a position in SAGE in Q2 2020 and held it in 2 quarters. The position peaked at $1.04M in Q2 2020. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Tarsadia Capital reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Tarsadia Capital sold 5,000 Sage Therapeutics shares in Q4 2020, an estimated $306K.
  • Tarsadia Capital first reported a position in Sage Therapeutics in Q2 2020 and held it in 2 quarters.
  • Tarsadia Capital's Sage Therapeutics position peaked at $1.04M in Q2 2020.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Tarsadia Capital's 13F filing for Q4 2020, filed 10 Feb 2021.